Macrovascular or microvascular complications
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events other than severe hypoglycaemic episodes (all non‐severe hypoglycaemic episodes) (Events per participant per month)
1 finding from 1 review
Socioeconomic effects
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Macrovascular complications
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Microvascular complications
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Costs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalization · patients submitted to transrectal prostate biopsy
Short course showed no clear difference in hospitalization compared with long course treatment (low certainty).
1 finding from 1 review
Bacteriuria · patients submitted to transrectal prostate biopsy
Short course probably leads to higher bacteriuria compared with long course treatment (moderate certainty).
1 finding from 1 review
Fever · patients submitted to transrectal prostate biopsy
Short course showed no clear difference in fever compared with long course treatment (moderate certainty).
1 finding from 1 review
UTI · patients submitted to transrectal prostate biopsy
Short course showed no clear difference in UTI compared with long course treatment (moderate certainty).
1 finding from 1 review
Mortality at time point closest to 90 days · participants with internal medicine diseases and conditions
It is very uncertain whether short‐stay unit hospitalisation changes mortality at time point closest to 90 days compared with usual care (very low certainty).
1 finding from 1 review
RR 0.73 [0.47, 1.15]
1294 participants
Very low
Serious adverse events at time point closest to 90 days · participants with internal medicine diseases and conditions
It is very uncertain whether short‐stay unit hospitalisation changes serious adverse events at time point closest to 90 days compared with usual care (very low certainty).
1 finding from 1 review
RR 0.95 [0.59, 1.54]
1907 participants
Very low
Quality of life at time point closest to 90 days · participants with internal medicine diseases and conditions
1 finding from 1 review
no estimate extracted
1029 participants
Very low
Activities of daily living · participants with internal medicine diseases and conditions
1 finding from 1 review
no estimate extracted
569 participants
Very low
Patient readmissions · participants with internal medicine diseases and conditions
It is very uncertain whether short‐stay unit hospitalisation changes hospital readmission at time point closest to 90 days compared with usual care (very low certainty).
1 finding from 1 review
RR 0.8 [0.54, 1.19]
1753 participants
Very low
Non‐serious adverse events at time point closest to 90 days · participants with internal medicine diseases and conditions
1 finding from 1 review
no estimate extracted
533 participants
Very low
Costs · participants with internal medicine diseases and conditions
1 finding from 1 review
no estimate extracted
1433 participants
Very low
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FEV1 (% predicted) compared with placebo (very low certainty).
1 finding from 1 review
Quality of life  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of exacerbations(as reported by number of hospitalisations and number of courses and days on antibiotics) · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes number of exacerbations(as reported by number of hospitalisations… compared with placebo (very low certainty).
1 finding from 1 review